Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- February 6, 2026 --

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial Globe Newswire 8:55 AM

-- February 5, 2026 --

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:40 AM

-- January 27, 2026 --

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering Globe Newswire 4:35 PM

-- January 23, 2026 --

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering Globe Newswire 1:22 PM

-- December 30, 2025 --

AIM ImmunoTech Announces Stock Dividend Globe Newswire 5:10 PM

-- December 10, 2025 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 9:00 AM

-- December 1, 2025 --

AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series Globe Newswire 8:55 AM

-- November 18, 2025 --

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program Globe Newswire 8:55 AM

-- November 10, 2025 --

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer Globe Newswire 8:55 AM

-- November 4, 2025 --

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Globe Newswire 9:05 AM

-- November 3, 2025 --

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue Globe Newswire 8:55 AM

-- October 20, 2025 --

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit Globe Newswire 9:15 AM

-- September 25, 2025 --

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors Globe Newswire 8:45 AM

-- September 22, 2025 --

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes